David Reardon, MD
Advertisement
Articles by David Reardon, MD
David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.
Advertisement
Latest Updated Articles
Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBMPublished: November 19th 2016 | Updated:
Dr. Reardon Discusses Rindopepimut Plus Bevacizumab in GlioblastomaPublished: November 15th 2014 | Updated:
Dr. Reardon on Updated Data From the Phase II ReACT TrialPublished: November 20th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5